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ABSTRACT 30 
Background: Small-scale studies correlated the presence of thyroid autoimmunity 31 
with both improved or worsened breast cancer outcome.  32 
Objectives: We aimed to clarify this association in a large cohort using the phase-III 33 
randomized controlled “Taxotere as Adjuvant Chemotherapy Trial” (TACT, CRUK01/001).  34 
Methods: TACT women >18-years-old with node-positive or high risk node-negative 35 
early breast cancer (pT1-3a,pN0-1,M0), with stored plasma (n=1974), taken 15.5 [7.0-24.0] 36 
months (median [IQR]) after breast surgery were studied. Patients had also received 37 
chemotherapy (100%), radiotherapy (1745/1974 [88.4%]), hormonal therapy (1378/1974 38 
[69.8%]), or trastuzumab (48/1974 [2.4%]). History of thyroid diseases and/or related 39 
treatments was not available. 40 
The prognostic significance of autoantibodies to thyroid peroxidase (TPOAb; positive ≥6 41 
kIU/L), free-thyroxine and thyrotropin (combined: euthyroid, hypothyroid, hyperthyroid) was 42 
evaluated for disease-free survival (DFS), overall-survival (OS), time-to-recurrence (TTR), 43 
with Cox regression models in univariate and multivariable analyses. The extended median 44 
follow-up was 97.5 months. 45 
Results: No difference in DFS was found by TPOAb status (unadjusted-hazard ratio 46 
[HR]: 0.97, 95%CI: 0.78-1.19, P=0.75) and/or thyroid function (unadjusted-HR [hypothyroid 47 
versus euthyroid]: 1.15, 95%CI: 0.79-1.68, P=0.46; unadjusted-HR [hyperthyroid versus 48 
euthyroid]: 1.14, 95%CI: 0.82-1.61, P=0.44). Similar results were obtained for OS, TTR, 49 
multivariable analyses, when TPOAb titre by tertiles was considered and in a subgroup of 123 50 
patients with plasma collected before adjuvant treatments.  51 
Conclusions: No evidence for a prognostic role of TPOAb and/or thyroid function in 52 
moderate-high risk early breast cancer was found in the largest and longest observational study 53 
to date.   54 
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INTRODUCTION 55 
An association between breast cancer (BC) and benign thyroid disorders has been 56 
debated for decades, reported in several [1,2], but not all [3] studies; the most recent meta-57 
analyses and reviews reached contrasting conclusions [1,4-6]. Hypothyroidism was found to 58 
correlate with both an increased [7,8] or reduced [9-11] risk of developing BC, whilst other 59 
authors did not report a significant correlation [12,13]. BC has been particularly associated 60 
with thyroid autoimmunity (TA); a higher prevalence of anti-thyroid peroxidase (TPO) 61 
autoantibodies (TPOAb) was found among BC patients, compared with healthy controls [8,14]. 62 
Furthermore, a better BC outcome has been reported in TPOAb positive (TPOAb+) versus 63 
TPOAb negative (TPOAb-) patients in some [15-18], but not all [19] studies.  64 
Currently no validated major blood prognostic markers for BC are available; 65 
carcinoembryonic antigen and cancer antigen 15.3 are the most used, but have low specificity 66 
and sensitivity [20]. Circulating tumour DNA and tumour cells seem very promising markers, 67 
however further studies are needed to validate them in routine clinical practice [21]. It would 68 
therefore be valuable if TPOAb could be confirmed as a blood BC prognostic marker.  69 
Two studies evaluated 5-year outcomes in 142 [15] and 47 [16] BC women: Smyth et 70 
al. [15] reporting TPOAb- as a poor prognostic factor for disease-free survival (DFS) and 71 
overall survival (OS), and Fiore et al. [16] reporting 6.7% mortality in patients positive for 72 
anti-thyroid autoantibodies (TAb), mainly TPOAb+, compared with 46.9% in TAb negative 73 
patients. Farahati et al. evaluated 314 newly diagnosed BC patients and found no distant 74 
metastases among TPOAb+ patients compared with 6.6% among TPOAb- patients [17]. In 75 
contrast, Jiskra et al. followed 84 BC patients for 136 months (median), finding no impact of 76 
TPOAb on DFS or OS [19]. 77 
The aim of the present study was to clarify the impact of TPOAb on BC prognosis in a 78 
large, well powered patient cohort with long-term follow-up, according to the “REporting 79 
recommendations for tumour MARKer prognostic studies (REMARK)” guidelines [22]. The 80 
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“Taxotere as Adjuvant Chemotherapy Trial (TACT)” recruited 4162 women diagnosed with 81 
moderate-high risk early BC, evaluating whether sequential docetaxel (Taxotere) after 82 
anthracycline therapy would improve patient outcome compared with standard anthracycline 83 
chemotherapy: analyses were conducted at 62 months [23] and 97.5 months [24] follow-up, 84 
both showing no evidence of a difference between the two chemotherapy regimens. Of 85 
relevance, stored plasma was available in a significant number of these patients.  86 
Furthermore, TPO is expressed in BC tissue [25], providing a possible mechanistic link: 87 
a thyroid/breast shared autoimmune response might target tumour cells and improve BC 88 
outcome. If TPOAb+ was confirmed as associated with a better BC outcome, new BC 89 
therapeutic approaches based on antigen-specific immunotherapies targeting TPO could be 90 
explored. 91 
 92 
MATERIALS AND METHODS 93 
Patients 94 
The TACT study [23] was a multicentre, open-label, phase-III, randomised controlled 95 
trial of women aged >18 years diagnosed with operable early BC (pT1-3a, pN0-1, M0), with 96 
indication for adjuvant chemotherapy, including both lymph-node positive (node+) patients 97 
and lymph-node negative (node-) but high risk (e.g., tumour grade 3, hormonal-receptor 98 
expression negative, or lymphovascular invasion) patients. 99 
 Between February 2001 and June 2003, 4162 women were enrolled across 103 UK 100 
and one Belgian centres. All subjects underwent surgery, mastectomy or wide-local-excision 101 
(WLE), and were randomized (1:1 ratio) to the experimental regimen FEC-D (n=2073; 102 
fluorouracil, epirubicin, cyclophosphamide [FEC] followed by docetaxel) or centre’s choice of 103 
control chemotherapy, either FEC (n=1265) or E-CMF (n=824; epirubicin followed by CMF 104 
[cyclophosphamide, methotrexate, and fluorouracil]). Adjuvant radiotherapy was mandatory 105 
after WLE or used after mastectomy according to local guidelines. Endocrine treatments 106 
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(tamoxifen or aromatase-inhibitor monotherapy, tamoxifen followed by aromatase-inhibitor) 107 
were administered to patients with oestrogen receptor (ER) positive expression (ER+). Patients 108 
with human epidermal growth factor receptor-2 (HER2) positive expression (HER2+) were 109 
allowed to enter clinical trials assessing trastuzumab. All subjects have given their informed 110 
consent and the study protocol has been approved by the institute's committee on human 111 
research. 112 
 113 
Laboratory measurements 114 
Following a protocol amendment (November 2002), blood was taken for future 115 
translational research at the time of randomization, or at their next follow-up visit. Plasma 116 
samples were stored at -20°C for 6.5-13 years (range) at The Institute of Cancer Research 117 
(London, UK), and transferred to the Thyroid Research Group (Cardiff, UK) for TPOAb, 118 
thyrotropin (TSH) and free-thyroxine (FT4) analyses (October 2014) using an ADVIA Centaur 119 
automated immunoassay analyser (Bayer plc, UK) and Chemiluminescent Microparticle 120 
Immunoassay methods by the ARCHITECT® System (ABBOTT Laboratories, USA). 121 
According to the assay cut-off, TPOAb values were dichotomized as ≥6 kIU/L (positive: 122 
TPOAb+) versus <6 kIU/L (negative: TPOAb-); TPOAb+ were also categorized into tertiles. 123 
FT4 and TSH normal ranges were 9.0–19.1 pmol/L and 0.30–4.40 mIU/L, respectively; they 124 
were also combined in a thyroid function status variable: euthyroid (FT4 and TSH within the 125 
normal ranges), hypothyroid (FT4 <9.0 pmol/L and/or TSH >4.40 mIU/L); hyperthyroid (FT4 126 
>19.1 pmol/L and/or TSH <0.3 mIU/L). 127 
 128 
Statistical analysis 129 
According to TPOAb prevalence in age-matched females of general population [26,27], 130 
20% of BC individuals were expected to be TPOAb+. Power calculations indicated 1158 and 131 
1430 samples required to provide respectively 80% and 90% power to detect a 81% 5-year 132 
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DFS in TPOAb+ versus 73% in TPOAb- subjects (HR, 0.64; two-sided log-rank test with a 133 
0.05 probability of a type I error), consistent with a 74.9% 5-year DFS rate in the whole TACT 134 
cohort [23]. 135 
Baseline characteristics, BC treatments and DFS-related characteristics were compared 136 
between TACT patients included or not in this study, and presented by dichotomized TPOAb 137 
and thyroid function status. Correlations between thyroid biomarkers were assessed using the 138 
Spearman rank method. 139 
The primary outcome was to assess TPOAb prognostic significance in relation to DFS; 140 
secondary outcomes were TPOAb prognostic significance in relation to OS and time-to-141 
recurrence (TTR), and thyroid function in relation to DFS, OS and TTR.  142 
For DFS, OS and TTR, Kaplan-Meier curves were plotted and biomarkers compared 143 
with the log-rank test, and assessed firstly in a univariate Cox proportional hazards regression 144 
model stratified by centre’s choice of control chemotherapy regimen and ER status, and 145 
subsequently included in a multivariable Cox model along with known BC prognostic factors: 146 
age, HER2 status, nodal involvement, tumour size and tumour grade. Additional variables, i.e. 147 
trial treatment (experimental versus control), type of surgery, trastuzumab use, radiotherapy 148 
and menopausal status, were included if, by stepwise selection (P<0.05), shown to add value. 149 
TPOAb, TSH and FT4 were subsequently considered for inclusion if providing independent 150 
prognostic information. Interaction tests were used to explore differential effects within 151 
subgroups. HR with 95% CI were obtained, with HR<1 indicating a better BC prognosis. 152 
All patients with a biomarker value available were included in the analysis, as per an 153 
intention-to-treat analysis. All analyses were conducted using Stata version 13.1 154 
(STATACORP, TX) [23,24]. 155 
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 156 
RESULTS 157 
All available TACT plasma samples (N=2000) were analysed for thyroid biomarkers, 158 
and 1974 samples were considered for the statistical analyses (“analysis population”; 159 
Supplemental Fig. 1). The median (IQR; range) blood collection time was 15.5 (7.0-24.0; 0.5–160 
57.2) months after surgery.   161 
 Supplemental Table 1 reports analysis population’s characteristics; the median (IQR; 162 
range) follow-up was 96.7 (87.4-106.3; 3.4-126.4) months. Overall 5-year estimates for DFS, 163 
OS and TTR were 79.5% (95% CI, 77.6-81.2), 87.4% (95% CI, 85.9-88.8) and 81.1% (95% 164 
CI, 79.3-82.8), respectively. 165 
 166 
Distribution of TPOAb and thyroid function 167 
TPOAb+ was detected in 406/1974 (20.6%) patients, distributed in the following 168 
tertiles: 137 (6.9%) 6-40 kIU/L (T1), 134 (6.7%) 41-238 kIU/L (T2), 135 (6.8%) 240-2000 169 
kIU/L (T3). Baseline characteristics were largely comparable between TPOAb+ and TPOAb- 170 
patients (Table 1), apart from age, with TPOAb+ patients slightly older than TPOAb- patients 171 
(mean [SD] age, 50.2 [7.7] years versus 48.8 [8.5] years, respectively; P=0.005).  172 
Plasma material was sufficient to determine FT4 and TSH values in 1974/1974 (100%) 173 
and 1971/1974 (99.8%) samples respectively. Among the 1974 patients, 1760 (89.2%) were 174 
euthyroid, 96 (4.9%) hypothyroid and 118 (6.0%) hyperthyroid; all 3 subgroups had similar 175 
baseline characteristics (Table 1), apart from age, with hypothyroid and hyperthyroid patients 176 
slightly older than euthyroid patients (mean [SD] age, respectively 50.5 [6.6] years and 50.7 177 
[7.6] years, versus 48.9 [8.5] years; P=0.03). 178 
As shown in Supplemental Fig. 2, FT4 and TSH were inversely correlated (Spearman 179 
rank, -0.23; P<0.001) and TPOAb was positively associated with TSH (Spearman rank, 0.24; 180 
P<0.001). The inverse correlation between TPOAb and FT4 was weak (Spearman rank, -0.04; 181 
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P=0.09). TPOAb+ cases were more prevalent among hypothyroid and hyperthyroid patients 182 
compared with the euthyroid group (73/96 [76.0%] hypothyroid; 45/118 [38.1%] hyperthyroid; 183 
288/1760 [16.4%] euthyroid; P<0.001).   184 
 185 
TPOAb and BC prognosis  186 
 The majority of DFS events were related to distant recurrence in both TPOAb+ and 187 
TPOAb- groups (Supplemental Table 2). There was no evidence of a difference in DFS 188 
between TPOAb+ and TPOAb- patients (unadjusted-HR: 0.97, 95% CI: 0.78-1.19, P=0.75, 189 
Fig. 1A; adjusted-HR: 1.00, 95% CI: 0.81-1.24, P=0.98, Table 2). Subgroup analyses showed 190 
no evidence of any significant interaction effects (Fig. 2). Similarly, there was no evidence of 191 
a difference by TPOAb status on OS (unadjusted-HR: 0.86, 95% CI: 0.66-1.11, P=0.24, Fig. 192 
1B; adjusted-HR: 0.89, 95% CI: 0.69-1.14, P=0.35, not shown) and TTR (unadjusted-HR: 0.97, 193 
95% CI: 0.78-1.21, P=0.80, Fig. 1C; adjusted-HR: 1.02, 95% CI: 0.81-1.27, P=0.89, not 194 
shown). TPOAb+ tertiles showed no evidence of a prognostic effect in both univariate (Fig. 3) 195 
and multivariable (data not shown) analyses for DFS, OS and TTR. 196 
Two sensitivity analyses included 126 node+ patients not treated with radiotherapy, 197 
similar to Fiore et al. cohort [16], and 123 patients with blood taken before any adjuvant 198 
therapy. The median (IQR; range) time of blood collection after surgery was 12.4 (4.9-21.6; 199 
0.7–47.2) months and 1.1 (0.9-1.4; 0.5-5.9) months, respectively. There was no evidence of a 200 
significant impact on DFS by TPOAb status in either of the two analyses, with unadjusted-HRs 201 
of 1.48 (95% CI, 0.68-3.25; P=0.32) and 0.83 (95% CI, 0.35-2.03; P=0.69) respectively. 202 
 203 
Thyroid function and BC prognosis 204 
There was no evidence of a significant difference for DFS, OS and TTR by thyroid 205 
function status in either univariate (Fig. 4) or multivariable (data not shown) analyses, and 206 
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when considering FT4 and TSH separately (DFS, Supplemental Table 3; OS and TTR, not 207 
shown).   208 
 209 
DISCUSSION 210 
In this large cohort of moderate-high risk early BC patients receiving adjuvant systemic 211 
treatments we found that neither the presence nor the titre of plasma TPOAb, assessed after 212 
BC diagnosis and measured with standard assays, had a substantial impact on long-term 213 
recurrence or mortality; similar findings were observed for thyroid status. These results 214 
confirm one previous finding [19], but contrast with two other studies [15,16]. We believe that 215 
our study is reliable, considering that our patient cohort is the largest to date, with one of the 216 
longest follow-ups, and focused on a well-defined BC population. Previous studies used 217 
smaller patient cohorts with shorter follow-ups [15,16,19], mixed different BC stages [19], or 218 
provided no information about BC stage [15], histological [15,19] and molecular subtypes 219 
[15,16,19], and adjuvant treatments received [15,19]; they may be susceptible to bias and 220 
random findings. In addition, the BC population analysed in this study is very similar to that 221 
of Fiore et al., who recruited non-metastatic aggressive BC all treated with chemotherapy [16]. 222 
The long survival of our patient cohort could obscure a minor prognostic effect of 223 
TPOAb and/or thyroid function on BC, hypothetically detectable only among patients not 224 
suitable for standard treatments (e.g. medical contraindications) and targeted therapies (e.g. 225 
triple negative BC). This is possible but unlikely, since our exploratory analysis conducted 226 
among different BC subtypes confirmed our negative results. Furthermore, the multivariable 227 
analyses confirmed nodal status and tumour size as the two most important BC prognostic 228 
factors [28], proving that the cohort used was appropriate for the research question, and the 229 
model reasonably sensitive. Similarly, the better BC prognosis characterizing the intermediate 230 
age group (50-59 years) is consistent with the results of a recent large cohort study [29]. 231 
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Our study cannot exclude a role of different TA parameters on BC prognosis, i.e. the 232 
presence of goitre [15] or incidental TA-related 18F-FDG PET/CT uptake [18]. Furthermore, 233 
differences in the alternative splicing of TPO in the breast as compared to the thyroid have 234 
been described [25], therefore this might also result in different TPO epitopes being targeted.  235 
TPOAb prevalence in our cohort, similar to our a priori predicted value, reflects 236 
TPOAb prevalence among women of general population [26,30], increasing with age [26,31]. 237 
It remains possible that TPOAb+ rates are higher in the BC population, as our study was not 238 
designed to compare TPOAb prevalence among BC patients and the general population. 239 
The principal limitations of the present study are the lack of clinical history for thyroid 240 
diseases or medications and that, similarly to previous studies [15,19], blood was mainly 241 
collected during/after adjuvant BC therapy. The first limitation might influence the prognostic 242 
role of thyroid function, but marginally of TPOAb, since they should exert an effect when 243 
either pre-existing, or appearing at a later time [32]; however, the evidence that thyroid function 244 
influences BC outcome is weak [6]. The finding of more cases of hyper- (6.0%) than hypo-245 
thyroidism (4.9%) may reflect over-treatment with levothyroxine in some individuals. 246 
Regarding BC adjuvant treatments, an increased risk of hypothyroidism after 247 
chemotherapy [33,34] or radiotherapy [35,36] for BC has been suggested in a few small 248 
studies, but not confirmed by others [37]. Tamoxifen can exert a modulation of thyroid 249 
function, mainly via an anti-thyroid effect [38,39] and the stress related to the surgical 250 
procedure itself has been suggested to cause immunomodulation [40]. However no clear large-251 
scale effects of adjuvant treatments for BC, including trastuzumab, on thyroid function and 252 
immunity have been described, and our sensitivity analysis in a subgroup of 123 patients in 253 
whom blood was collected before BC adjuvant therapy showed no evidence of TPOAb 254 
prognostic ability, even if the wide 95% CI suggests a lack of statistical power.  255 
To draw definitive conclusions, a prospective study collecting blood before cancer 256 
treatments would be ideal, but difficult to realise because of the large patient number required, 257 
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as shown by our a priori power calculation. Furthermore, this study analysed moderate-high 258 
risk early BC only. BC is a heterogeneous disease, with many subtypes characterised by 259 
different clinical behaviour and prognosis; it could be possible that TPOAb and/or thyroid 260 
function affect the prognosis of certain specific BC subtypes and stages only, therefore they 261 
should be all investigated separately, with a much higher total patient numbers required to 262 
reach significant and definitive results. 263 
In conclusion, the present study is to our knowledge the largest currently available 264 
investigating the impact of blood TPOAb and thyroid function on BC prognosis, providing a 265 
detailed description of the BC population analysed, and therefore representing a key-work to 266 
clarify this debate over decades. We found that TPOAb and thyroid function, both measured 267 
with standard assays and after BC diagnosis, appear not to influence substantially the long-268 
term recurrence and mortality of moderate-high risk early BC in the modern era. Major 269 
confounding in this conclusion due to BC treatments seems unlikely. Future studies might 270 
explore different BC stages and/or specific subtypes, also searching for non-conventional or 271 
breast-specific immune responses to particular TPO epitopes, to determine whether aspects of 272 
TA other than standard TPOAb and thyroid function may be relevant to BC outcome.   273 
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TABLES 415 
Table 1: Baseline characteristics and treatments for breast cancer by autoantibodies to thyroid peroxidase (TPOAb) and thyroid function status 416 
 TPOAb- 
N = 1568 
TPOAb+ 
N = 406 
P value Hypothyroid 
N = 96 
Euthyroid 
N = 1760 
Hyperthyroid 
N = 118 
P value 
Age (years): mean (SD)  48.8 (8.5) 50.2 (7.7) 0.005a 50.5 (6.6) 48.9 (8.5) 50.7 (7.6) 0.03d 
Age group (years): n (%)    
0.08b 
   
0.62b 
     <40 257 (16.4) 49 (12.1) 8 (8.3) 287 (16.3) 11 (9.3) 
     40-49 575 (36.7) 151 (37.2) 36 (37.5) 647 (36.8) 43 (36.4) 
     50-59 590 (37.6) 167 (41.1) 45 (46.9) 657 (37.3) 55 (46.6) 
     ≥60 146 (9.3) 39 (9.6) 7 (7.3) 169 (9.6) 9 (7.6) 
Nodal status: n (%)    
0.62b 
   
0.61b 
     Node negative 314 (20.0) 93 (22.9) 18 (18.8) 367 (20.9) 22 (18.6) 
     1-3 positive nodes 719 (45.9) 171 (42.1) 33 (34.4) 808 (45.9) 49 (41.5) 
     ≥4 positive nodes 535 (34.1) 142 (35.0) 45 (46.9) 585 (33.2) 47 (39.8) 
Tumour grade: n (%)    
0.74b 
   
0.72b 
     Grade 1 77 (4.9) 23 (5.7) 4 (4.2) 88 (5.0) 8 (6.8) 
     Grade 2 603 (38.5) 155 (38.2) 35 (36.5) 681 (38.7) 42 (35.6) 
     Grade 3 883 (56.3) 228 (56.2) 57 (59.4) 986 (56.0) 68 (57.6) 
     Unknown 5 (0.3) 0 (0.0) 0 (0.0) 5 (0.3) 0 (0.0) 
Tumour size (cm): n (%)    
0.59b 
   
0.38b 
     ≤2 578 (36.9) 147 (36.2) 25 (26.0) 659 (37.4) 41 (34.8) 
     >2 and ≤5 857 (54.7) 220 (54.2) 61 (63.5) 952 (54.1) 64 (54.2) 
     >5 132 (8.4) 39 (9.6) 10 (10.4) 148 (8.4) 13 (11.0) 
     Unknown 1 (0.1) 0 (0.0) 0 (0.0) 1 (0.1) 0 (0.0) 
ER & HER2 status: n (%)   
0.85c (ER) 
0.45c (HER2) 
   
0.62c (ER) 
0.84c (HER2) 
     ER+ 1107 (70.6) 289 (71.2) 69 (71.9) 1248 (70.9) 79 (67.0) 
           & HER2+ 198 (12.6) 49 (12.1) 13 (13.5) 220 (12.5) 14 (11.9) 
           & HER2- 772 (49.2)  201 (49.5) 46 (47.9) 873 (49.6) 54 (45.8) 
           & HER2 unknown 137 (8.7) 39 (9.6) 10 (10.4) 155 (8.8) 11 (9.3) 
     ER- 461 (29.4) 117 (28.8) 27 (28.1) 512 (29.1) 39 (33.1) 
           & HER2+ 118 (7.5) 43 (10.6) 8 (8.3) 141 (8.0) 12 (10.2) 
           & HER2- 289 (18.4) 61 (15.0) 15 (15.6) 313 (17.8) 22 (18.6) 
           & HER2 unknown 54 (3.4) 13 (3.2) 4 (4.2) 58 (3.3) 5 (4.2) 
Molecular subgroup: n (%)    
0.40c 
   
0.94c 
     ER+/HER2-1 784 (50.0) 203 (50.0) 47 (49.0) 885 (50.3) 55 (46.6) 
     HER2+ 316 (20.2) 92 (22.7) 21 (21.9) 361 (20.5) 26 (22.0) 
     Triple negative 277 (17.7) 59 (14.5) 14 (14.6) 301 (17.1) 21 (17.8) 
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 TPOAb- 
N = 1568 
TPOAb+ 
N = 406 
P value Hypothyroid 
N = 96 
Euthyroid 
N = 1760 
Hyperthyroid 
N = 118 
P value 
Type of surgery and 
radiotherapy use: n (%)  
  
0.74c 
(surgery) 
0.61c 
(radiotherapy) 
   
0.99c 
(surgery) 
0.33c 
(radiotherapy) 
     Mastectomy 854 (54.5) 225 (55.4) 53 (55.2) 962 (54.7) 64 (54.2) 
          with radiotherapy ^ 688 (80.6 ) 177 (78.7) 47 (88.7) 772 (80.2) 46 (71.9) 
     Wide local excision 714 (45.5) 181 (44.6) 43 (44.8) 798 (45.3) 54 (45.8) 
          with radiotherapy # 704 (98.6) 176 (97.2) 41 (95.3) 787 (98.6) 52 (96.3) 
Endocrine treatment in ER+ 
patients: n (%)* 
  
0.13c 
   
0.09c 
     Tamoxifen monotherapy 696 (62.9) 167 (57.8) 43 (62.3) 772 (61.9) 48 (60.8) 
     Tamoxifen followed by AI 354 (32.0) 100 (34.6) 20 (29.0) 409 (32.8) 25 (31.7) 
     AI monotherapy 46 (4.2) 15 (5.2) 6 (8.7) 53 (4.3) 2 (2.5) 
     No endocrine 
treatment/unknown 
11 (1.0) 7 (2.4) 0 (0.0) 14 (1.1) 4 (5.1) 
Trastuzumab in HER2+ 
patients: n (%)** 
  
0.36c 
   
0.71c 
     Yes 40 (12.7) 8 (8.7) 1 (4.8) 44 (12.2) 3 (11.5) 
     No/Not known 276 (87.3) 84 (91.3) 20 (95.2) 317 (87.8) 23 (88.5) 
Chemotherapy: n (%)   
0.52c 
   
0.90c 
     Control (FEC) 498 (31.8) 128 (31.5) 27 (28.1) 568 (32.3) 31 (26.3) 
     Control (E-CMF) 271 (17.3) 61 (15.0) 16 (16.7) 301 (17.1) 15 (12.7) 
     FEC-D 799 (51.0) 217 (53.4) 53 (55.2) 891 (50.6) 52 (44.1) 
     1 includes ER-, PgR+, HER2-     417 
     ^  denominators calculated using patients treated with mastectomy 418 
        #  denominators calculated using patients treated with wide local excision 419 
     * denominators calculated using ER+ patients 420 
     ** denominators calculated using HER2+ patients 421 
     a t-test 422 
     b trend test; note “unknowns” excluded from the test 423 
     c Fisher’s exact test 424 
     d ANOVA 425 
 426 
AI, aromatase-inhibitors; ER+, positive estrogen receptor (ER); ER-, negative ER; E-CMF, epirubicin 100 mg/m2 for 4 cycles followed by CMF 427 
(cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2 and fluorouracil 600 mg/m2) for 4 cycles; FEC, fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and 428 
cyclophosphamide 600 mg/m2 for 8 cycles; FEC-D, FEC for 4 cycles followed by docetaxel 100 mg/m2 for 4 cycles; HER2+, positive human epidermal growth 429 
factor receptor-2 (HER2); HER2-, negative HER2; PgR+, positive progesterone receptor (PgR); SD, standard deviation; TPOAb+, positive TPOAb; TPOAb-, 430 
negative TPOAb; triple negative, negative HER2, ER and PgR. 431 
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Table 2: Multivariable analysis for disease-free survival by dichotomized autoantibodies to 432 
thyroid peroxidase (TPOAb) 433 
 434 
 HR 95% CI P value 
TPOAb status negative (n=1568) 1.00 - - 
positive (n=406) 1.00 0.81-1.24 0.98 
Nodal status positive (n=1567) 1.00 - - 
negative (n=407) 0.49 0.37-0.64 < 0.001 
HER2 status negative (n=1323) 1.00 - - 
positive (n=408) 1.19 0.97-1.46 0.09 
unknown (n=243) 0.93 0.71-1.23 0.63 
Age group (years) <40 (n=306) 1.00 - - 
40-49 (n=726) 0.78 0.61-1.00 0.05 
50-59 (n=757) 0.75 0.59-0.96 0.02 
≥60 (n=185) 0.95 0.69-1.31 0.76 
Tumour grade Grade 1 (n=100) 1.00 - - 
Grade 2 (n=758) 1.15 0.74-1.78 0.55 
Grade 3 (n=1111) 1.39 0.89-2.17 0.14 
unknown (n=5) 0.77 0.10-5.75 0.80 
Tumour size (cm) * ≤2 (n=725) 1.00 - - 
>2 and ≤5 (n=1077) 1.37 1.12-1.66 0.002 
>5 (n=171) 1.88 1.41-2.52 < 0.001 
Type of surgery Mastectomy (n=1079) 1.00 - - 
WLE (n=895) 0.79 0.66-0.95 0.01 
 435 
HER2, human epidermal growth factor receptor-2; HR, hazard ratio (HR <1 indicates a favorable 436 
breast cancer outcome); WLE, wide local excision; 95% CI, 95% confidence interval.  437 
* The patient with unknown tumour size (n=1) has not been considered for this analysis. 438 
  439 
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FIGURES 440 
 441 
Fig. 1: Univariate analyses by dichotomized autoantibodies to thyroid peroxidase 442 
(TPOAb) 443 
 444 
Kaplan-Meier curves relative to breast cancer (BC) outcome (median follow-up 96.7 months) 445 
in patients positive (≥6 kIU/L) and negative (<6 kIU/L) for TPOAb. HR, hazard ratio (HR <1 446 
indicates a favorable BC outcome); 95% CI, 95% confidence interval. Panel A: disease-free 447 
survival (DFS). Panel B: overall survival (OS). Panel C: time to recurrence (TTR). 448 
  449 
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Fig. 2: Exploratory subgroup analyses for disease-free survival by dichotomized 450 
autoantibodies to thyroid peroxidase (TPOAb) 451 
 452 
ER+, positive estrogen receptor (ER); ER-, negative ER; HER2+, positive human epidermal 453 
growth factor receptor-2 (HER2); HER2-, negative HER2; NK, not known; N-, lymph-node 454 
negative; N1-3+, 1-3 lymph-nodes positive, N4+, 4 or more lymph-nodes positive; TPOAb+, 455 
positive TPOAb; TPOAb-, negative TPOAb; triple negative, negative HER2, ER and 456 
progesterone receptor; WLE, wide local excision; 95% CI, 95% confidence interval. 457 
  458 
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Fig. 3: Univariate analyses by autoantibodies to thyroid peroxidase (TPOAb) categorized 459 
into tertiles 460 
 461 
Kaplan-Meier curves relative to breast cancer (BC) outcome (median follow-up 96.7 months) 462 
in patients negative (<6 kIU/L) and positive for TPOAb categorized into tertiles: 6-40 kIU/L 463 
(T1), 41-238 kIU/L (T2), 240-2000 kIU/L (T3). HR, hazard ratio (HR <1 indicates a favorable 464 
BC outcome); 95% CI, 95% confidence interval. Panel A: disease-free survival (DFS). Panel 465 
B: overall survival (OS). Panel C: time to recurrence (TTR). 466 
  467 
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Fig. 4: Univariate analyses by thyroid function status 468 
 469 
Kaplan-Meier curves relative to breast cancer (BC) outcome (median follow-up 96.7 months) 470 
according to thyroid function status. Euthyroid, free-thyroxine (FT4) 9.0–19.1 pmol/L and 471 
thyrotropin (TSH) 0.30–4.40 mIU/L; hyperthyroid, FT4 >19.1 pmol/L and/or TSH <0.3 472 
mIU/L; hypothyroid, FT4 <9.0 pmol/L and/or TSH >4.40 mIU/L. HR, hazard ratio (HR <1 473 
indicates a favorable BC outcome); 95% CI, 95% confidence interval. Panel A: disease-free 474 
survival (DFS). Panel B: overall survival (OS). Panel C: time to recurrence (TTR). 475 
  476 
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SUPPLEMENTAL MATERIAL 477 
 478 
Supplemental Table 1: Baseline characteristics, treatments for breast cancer and disease-free 479 
survival (DFS) related characteristics  480 
 481 
 
Analysis population 
N = 1974 
Not included 
patients 
N = 2188 
All TACT trial 
patients 
N = 4162 
Age (years), mean (SD) 49.1 (8.4) 48.2 (8.6) 48.6 (8.5) 
Age group (years), n (%)    
     <40 306 (15.5) 412 (18.8) 718 (17.3) 
     40-49 726 (36.8) 841 (38.4) 1567 (37.7) 
     50-59 757 (38.4) 730 (33.4) 1487 (35.7) 
     ≥60 185 (9.4) 205 (9.4) 390 (9.4) 
Nodal status, n (%)    
     Node negative 407 (20.6) 428 (19.6) 835 (20.1) 
     1-3 positive nodes 890 (45.1) 949 (43.4) 1839 (44.2) 
     ≥4 positive nodes 677 (34.3) 811 (37.1) 1488 (35.8) 
Tumor grade, n (%)    
     Grade 1 100 (5.1) 129 (5.9) 229 (5.5) 
     Grade 2 758 (38.4) 778 (35.6) 1536 (36.9) 
     Grade 3 1111 (56.3) 1271 (58.1) 2382 (57.2) 
     Unknown 5 (0.3) 10 (0.5) 15 (0.4) 
Tumor size (cm), n (%)     
     ≤2 725 (36.7) 711 (32.5) 1436 (34.5) 
     >2 and ≤5 1077 (54.6) 1253 (57.3) 2330 (56.0) 
     >5 171 (8.7) 221 (10.1) 392 (9.4) 
     Unknown 1 (0.1) 3 (0.1) 4 (0.1) 
ER & HER2 status, n (%)    
     ER+ 1396 (70.7) 1479 (67.6) 2875 (69.1) 
           & HER2+ 247 (12.5) 247 (11.3) 494 (11.9) 
           & HER2- 973 (49.3) 990 (45.2) 1963 (47.2) 
           & HER2 unknown 176 (8.9) 242 (11.1) 418 (10.0) 
     ER- 578 (29.3) 709 (32.4) 1287 (30.9) 
           & HER2+ 161 (8.2) 194 (8.9) 355 (8.5) 
           & HER2- 350 (17.7) 411 (18.8) 761 (18.3) 
           & HER2 unknown 67 (3.4) 104 (4.8) 171 (4.1) 
Molecular subgroup, n (%)    
     ER+/HER2-* 987 (50.0) 1014 (46.3) 2001 (48.1) 
     HER2+ 408 (20.7) 441 (20.2) 849 (20.4) 
     Triple negative 336 (17.0) 387 (17.7) 723 (17.4) 
Type of surgery and radiotherapy, n (%)    
     Mastectomy 1079 (54.7) 1186 (54.2) 2265 (54.4) 
          with radiotherapy 865 (43.8) 949 (43.4) 1814 (43.6) 
breast 159 (8.1) 254 (11.6) 413 (9.9) 
chest wall 709 (35.9) 693 (31.7) 1402 (33.7) 
supraclavicular fossa 480 (24.3) 500 (22.9) 980 (23.5) 
axilla 85 (4.3) 103 (4.7) 188 (4.5) 
     Wide local excision 895 (45.3) 1002 (45.8) 1897 (45.6) 
          with radiotherapy 880 (44.6) 961 (43.9) 1841 (44.2) 
breast 856 (43.4) 921 (42.1) 1777 (42.7) 
chest wall 31 (1.6) 47 (2.1) 78 (1.9) 
supraclavicular fossa 291 (14.7) 283 (12.9) 574 (13.8) 
axilla 103 (5.2) 70 (3.2) 173 (4.2) 
Endocrine treatment in ER+ patients, n (%)    
     Tamoxifen monotherapy 863 (61.8) 927 (62.7) 1790 (62.3) 
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Analysis population 
N = 1974 
Not included 
patients 
N = 2188 
All TACT trial 
patients 
N = 4162 
     Tamoxifen followed by AI 454 (32.5) 439 (29.7) 893 (31.1) 
     AI monotherapy 61 (4.4) 76 (5.1) 137 (4.8) 
     No endocrine treatment/unknown 18 (1.3) 37 (2.5) 55 (1.9) 
Trastuzumab in HER2+ patients, n (%)    
     Yes 48 (11.8) 28 (6.4) 76 (9.0) 
     No/Not known 360 (88.2) 413 (93.7) 773 (91.0) 
Chemotherapy, n (%)    
     Control (FEC) 626 (31.7) 639 (29.2) 1265 (30.4) 
     Control (E-CMF) 332 (16.8) 492 (22.5) 824 (19.8) 
     FEC-D 1016 (51.5) 1057 (48.3) 2073 (49.5) 
Number of patients with event contributing to DFS 
analysis 
551 (27.9) 778 (35.6) 1329 (31.9) 
     Local recurrence 76 (3.8) 107 (4.9) 183 (4.4) 
     Distant recurrence 405 (20.5) 572 (26.1) 977 (23.5) 
     New breast disease 43 (2.2) 44 (2.0) 91 (2.2) 
     Death from other cause (no recurrence) 27 (1.4) 51 (2.3) 78 (1.9) 
Distant relapse ever reported 462 (23.4) 655 (29.9) 1117 (26.8) 
New breast disease ever reported 57 (2.9) 67 (3.1) 124 (3.0) 
All non-breast cancer second primary 52 (2.6) 54 (2.5) 106 (2.5) 
All deaths 397 (20.1) 620 (28.3) 1017 (24.4) 
     Breast cancer 369 (18.7) 568 (26.0) 937 (22.5) 
     Death from other causes  28 (1.4) 52 (2.4) 80 (1.9) 
          Cancer (non-breast) 15 (0.8) 21 (1.0) 36 (0.9) 
          Treatment toxicity 0 5 (0.2) 5 (0.1) 
          Other 13 (0.7) 26 (1.2) 39 (0.9) 
 482 
* includes ER-, PgR+, HER2- 483 
 484 
AI, aromatase-inhibitors; ER+, positive estrogen receptor (ER); ER-, negative ER; E-CMF, epirubicin 485 
100 mg/m2 for 4 cycles followed by CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2 and 486 
fluorouracil 600 mg/m2) for 4 cycles; FEC, fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and 487 
cyclophosphamide 600 mg/m2 for 8 cycles; FEC-D, FEC for 4 cycles followed by docetaxel 100 mg/m2 488 
for 4 cycles; HER2+, positive human epidermal growth factor receptor-2 (HER2); HER2-, negative 489 
HER2; PgR+, positive progesterone receptor (PgR); SD, standard deviation; TACT, “Taxotere as 490 
adjuvant chemotherapy trial”; TPOAb, autoantibodies to thyroid peroxidase. 491 
  492 
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Supplemental Table 2: Events contributing to disease-free survival (DFS) and numbers of deaths 493 
by dichotomized TPOAb status 494 
 495 
 
TPOAb- (N = 1568) 
n (%) 
TPOAb+ (N = 406) 
n (%) 
Number of patients with event contributing to 
DFS analysis 
442 (28.2) 109 (26.8) 
     Local recurrence 59 (3.8) 17 (4.2) 
     Distant recurrence 327 (20.9) 78 (19.2) 
     New breast disease 33 (2.1) 10 (2.5) 
     Death from other cause (no recurrence) 23 (1.5) 4 (1.0) 
All deaths 325 (20.7) 72 (17.7) 
     Breast cancer 301 (19.2) 68 (16.7) 
Death from other causes (without distant 
recurrence) 
24 (1.5) 4 (1.0) 
          Cancer (non-breast) 14 (0.9) 1 (0.2) 
          Treatment toxicity 0 (0.0) 0 (0.0) 
          Other 9 (0.6) 3 (0.7) 
               Vascular (cardiac) 1 (0.1) 1 (0.2) 
               Vascular (cerebral) 1 (0.1) 0 (0.0) 
               Vascular (thromboembolic) 0 (0.0) 0 (0.0) 
               Respiratory 0 (0.0) 0 (0.0) 
               Accident, suicide, alcoholism 5 (0.3) 0 (0.0) 
               Infection (not treatment related) 0 (0.0) 1 (0.2) 
               Gastrointestinal bleed 0 (0.0) 0 (0.0) 
               Chronic liver disease 1 (0.1) 0 (0.0) 
               Unknown 2 (0.1) 1 (0.2) 
 496 
TPOAb+, positive autoantibodies to thyroid peroxidase (TPOAb); TPOAb-, negative TPOAb. 497 
  498 
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Supplemental Table 3: Univariate analyses for disease-free survival by FT4 and TSH 499 
Variable 
Unadjusted 
HR 
95% CI P value 
FT4 
 Continuous 1.00 0.96-1.04 0.91 
    
<9.0 pmol/L (Hypothyroid; n=13) 1.61 0.67-3.88 0.29 
9.0–19.1 pmol/L (Euthyroid; n=1917) 1.00 - - 
>19.1 pmol/L (Hyperthyroid; n=44) 1.08 0.62-1.87 0.79 
     
TSH* 
Continuous 1.03 0.94-1.13 0.48 
    
>4.40 mIU/L (Hypothyroid; n=94) 1.08 0.73-1.59 0.71 
0.3-–4.40 mIU/L (Euthyroid; n=1781) 1.00 - - 
<0.3 mIU/L (Hyperthyroid; n=96) 1.19 0.82-1.72 0.36 
 500 
FT4, free-thyroxine; HR, hazard ratio (HR <1 indicates a favorable breast cancer outcome); TSH, 501 
thyrotropin; 95% CI, 95% confidence interval.  502 
*TSH value was available in 1971/1974 (99.8%) samples 503 
  504 
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Supplemental Fig. 1: Flowchart regarding sample availability and data handling 505 
 506 
FT4, free-thyroxine; TPOAb, autoantibodies to thyroid peroxidase; TSH, thyrotropin. 507 
  508 
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Supplemental Fig. 2: Correlation between thyroid markers 509 
510 
FT4, free-thyroxine; TPOAb, autoantibodies to thyroid peroxidase; TSH, thyrotropin. Panel A: 511 
inverse correlation between TSH (logarithmic scale) and FT4. Panel B: positive correlation 512 
 33 
between TPOAb and TSH (logarithmic scale).  Panel C: inverse correlation between TPOAb 513 
and FT4. 514 
